La Chaux-de-Fonds, Switzerland, Sept. 9, 2013 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals announces a scientific poster presentation on the PI3K-delta inhibitor, TGR-1202, by the Duke University Medical Center, on 9th September 2013, at the IWCLL workshop in Cologne, Germany.
TGR-1202 (formerly known as RP5264) is an orally available PI3K delta inhibitor, targeting the delta isoform with nanomolar potency and having high selectivity over the alpha, beta, and gamma isoforms of PI3K. The delta isoform of PI3K is predominantly expressed in cells of hematopoietic origin and because the isoform contributes to the development, maintenance, transformation, and proliferation of B-cells, targeting PI3K delta represents a promising approach for the treatment of B-cell malignancies.
Rhizen has partnered TGR-1202 with TG Therapeutics, USA, as a global joint venture.TGR-1202 is currently in Phase I clinical development for patients with hematologic malignancies.
Details of the presentation:
- Abstract: "The PI3K-delta inhibitor TGR-1202 induces cytotoxicity and inhibits phosphorylation of AKT in 17p deleted and non-17p deleted CLL cells in vitro"
- Time and Location- Poster Session on Monday, 9 September 2013 between 16.35 - 18.15 at the XV International Workshop on Chronic Lymphocytic Leukaemia to be held at the Maritim Hotel, Cologne, Germany.
About Rhizen Pharmaceuticals SA:
Rhizen is a biopharmaceutical company focused on the discovery and development of novel therapeutics targeted to treat cancer, immune and metabolic disorders. Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways. Rhizen is headquartered in La-Chaux-de-Fonds, Switzerland. For additional information, please visit Rhizen's website (www.rhizen.com).
A photo accompanying this release is available at:
http://www.globenewswire.com/newsroom/prs/?pkgid=20843
